In sensitivity analyses, median overall persistence to any PAH drug class was higher than persistence to index class as follows: index class parenteral PPA (11.2 months), PDE5i (8.9 months), oral PPA (40.1 months), sGC stimulators (20.0 months), and ERA (32.5 months). Here, SGCB is linked to pulmonary arterial hypertension.